Regeneron Pharma (REGN) Price Target Raised to $455 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St futures kick off September under pressure as yields, oil prices rise
- Oil rises as renewed US-Iran strikes stoke supply fears
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
Regeneron Pharma (REGN) Price Target Raised to $410 at RBC
November 4, 2014 3:28 PM ESTRBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $410.00 (from $373.00). Comments follow Q3 results. Analyst Adnan Butt said he was a buyer of pullbacks.
"While ramp from DME did not materialize, the... More
Regeneron (REGN) Misses Q3 EPS by 5c
November 4, 2014 6:31 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $2.52, $0.05 worse than the analyst estimate of $2.57. Revenue for the quarter came in at $726 million versus the consensus estimate of $733.04 million.
Pipeline Progress
Regeneron has sixteen fully human monoclonal antibodies generated using the Company's VelocImmune® technology in clinical development, including six in collaboration with Sanofi. Highlights from the late-stage antibody pipeline include:
Alirocumab, the Company's antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) to lower LDL-cholesterol (LDL-C), is currently being evaluated in the global Phase 3 ODYSSEY program. In July 2014, the Company and Sanofi reported... More
